Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

John Imig to Kidney

This is a "connection" page, showing publications John Imig has written about Kidney.

 
Connection Strength
  
 
 
8.049
  
  1. Imig JD, Hye Khan MA, Burkhan A, Chen G, Adebesin AM, Falck JR. Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. Int J Mol Sci. 2021 Mar 10; 22(6).
    View in: PubMed
    Score: 0.536
  2. Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension. 2020 07; 76(1):3-15.
    View in: PubMed
    Score: 0.508
  3. Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins Other Lipid Mediat. 2016 09; 125:40-7.
    View in: PubMed
    Score: 0.388
  4. Yeboah MM, Hye Khan MA, Chesnik MA, Sharma A, Paudyal MP, Falck JR, Imig JD. The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. Am J Physiol Renal Physiol. 2016 09 01; 311(3):F576-85.
    View in: PubMed
    Score: 0.387
  5. Imig JD, Khan MA. Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. Compr Physiol. 2015 Dec 15; 6(1):423-41.
    View in: PubMed
    Score: 0.373
  6. Hye Khan MA, Neck?r J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD. Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension. 2013 Nov; 62(5):905-13.
    View in: PubMed
    Score: 0.318
  7. Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 2013 Aug; 27(8):2946-56.
    View in: PubMed
    Score: 0.310
  8. Imig JD. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:2-7.
    View in: PubMed
    Score: 0.305
  9. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol. 2011 Nov; 301(5):R1307-17.
    View in: PubMed
    Score: 0.276
  10. Imig JD, Dimitropoulou C, Reddy DS, White RE, Falck JR. Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. Microcirculation. 2008 Feb; 15(2):137-50.
    View in: PubMed
    Score: 0.216
  11. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension. 2008 Feb; 51(2):352-9.
    View in: PubMed
    Score: 0.215
  12. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD. Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension. 2007 Dec; 50(6):1069-76.
    View in: PubMed
    Score: 0.212
  13. Zhao X, Quigley JE, Yuan J, Wang MH, Zhou Y, Imig JD. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2006 Jun; 290(6):H2187-95.
    View in: PubMed
    Score: 0.189
  14. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension. 2006 Mar; 47(3):557-62.
    View in: PubMed
    Score: 0.188
  15. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F496-503.
    View in: PubMed
    Score: 0.183
  16. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004 May; 15(5):1244-53.
    View in: PubMed
    Score: 0.167
  17. Imig JD. ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. Hypertension. 2004 Mar; 43(3):533-5.
    View in: PubMed
    Score: 0.164
  18. Goorani S, Khan AH, Mishra A, El-Meanawy A, Imig JD. Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences. Kidney Blood Press Res. 2024; 49(1):69-80.
    View in: PubMed
    Score: 0.163
  19. Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension. 2003 Oct; 42(4):775-80.
    View in: PubMed
    Score: 0.158
  20. Imig JD, Zhao X, Orengo SR, Dipp S, El-Dahr SS. The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. Peptides. 2003 Aug; 24(8):1141-7.
    View in: PubMed
    Score: 0.158
  21. Imig JD, Khan MAH, Stavniichuk A, Jankiewicz WK, Goorani S, Yeboah MM, El-Meanawy A. Salt-sensitive hypertension after reversal of unilateral ureteral obstruction. Biochem Pharmacol. 2023 04; 210:115438.
    View in: PubMed
    Score: 0.153
  22. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension. 2003 Mar; 41(3 Pt 2):709-14.
    View in: PubMed
    Score: 0.152
  23. Imig JD, Breyer MD, Breyer RM. Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. Am J Physiol Renal Physiol. 2002 Sep; 283(3):F415-22.
    View in: PubMed
    Score: 0.148
  24. Imig JD. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury. Adv Pharmacol. 2022; 94:27-55.
    View in: PubMed
    Score: 0.144
  25. Khan MAH, Hwang SH, Barnett SD, Stavniichuk A, Jankiewicz WK, Hammock BD, Imig JD. Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats. Br J Pharmacol. 2021 11; 178(22):4468-4484.
    View in: PubMed
    Score: 0.138
  26. Imig JD, Merk D, Proschak E. Multi-Target Drugs for Kidney Diseases. Kidney360. 2021 10 28; 2(10):1645-1653.
    View in: PubMed
    Score: 0.138
  27. Sedl?kov? L, Kikerlov? S, Huskov? Z, Cervenkov? L, Ch?bov? VC, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kr?tk? V, Cervenka L, Kopkan L. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep. 2018 10 31; 38(5).
    View in: PubMed
    Score: 0.113
  28. Miller BS, Blumenthal SR, Shalygin A, Wright KD, Staruschenko A, Imig JD, Sorokin A. Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats. Diabetes. 2018 11; 67(11):2206-2212.
    View in: PubMed
    Score: 0.112
  29. Miller B, Palygin O, Rufanova VA, Chong A, Lazar J, Jacob HJ, Mattson D, Roman RJ, Williams JM, Cowley AW, Geurts AM, Staruschenko A, Imig JD, Sorokin A. p66Shc regulates renal vascular tone in hypertension-induced nephropathy. J Clin Invest. 2016 07 01; 126(7):2533-46.
    View in: PubMed
    Score: 0.096
  30. Hye Khan MA, Fish B, Wahl G, Sharma A, Falck JR, Paudyal MP, Moulder JE, Imig JD, Cohen EP. Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clin Sci (Lond). 2016 Apr; 130(8):587-99.
    View in: PubMed
    Score: 0.094
  31. Hye Khan MA, Neck?r J, Cummens B, Wahl GM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther. 2014 Aug; 28(4):313-22.
    View in: PubMed
    Score: 0.085
  32. Capdevila JH, Pidkovka N, Mei S, Gong Y, Falck JR, Imig JD, Harris RC, Wang W. The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J Biol Chem. 2014 Feb 14; 289(7):4377-86.
    View in: PubMed
    Score: 0.081
  33. Varcabova S, Huskova Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Kitada K, Cervenka L. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. Clin Exp Pharmacol Physiol. 2013 Apr; 40(4):273-81.
    View in: PubMed
    Score: 0.077
  34. Honetschl?gerov? Z, Kitada K, Huskov? Z, Sporkov? A, Kopkan L, B?rgelov? M, Varcabov? ?, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Cervenka L. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens. 2013 Feb; 31(2):321-32.
    View in: PubMed
    Score: 0.076
  35. Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. Am J Physiol Renal Physiol. 2011 Oct; 301(4):F765-72.
    View in: PubMed
    Score: 0.069
  36. Sporkov? A, Kopkan L, Varcabov? S, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2011 Jun; 300(6):R1468-75.
    View in: PubMed
    Score: 0.067
  37. Honetschl?gerov? Z, Huskov? Z, Vanourkov? Z, Sporkov? A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Cervenka L, Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011 Jan 01; 589(Pt 1):207-19.
    View in: PubMed
    Score: 0.066
  38. Walkowska A, Skaroupkov? P, Huskov? Z, Vanourkov? Z, Ch?bov? VC, Tesar V, Kramer HJ, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L. Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J Hypertens. 2010 Mar; 28(3):582-93.
    View in: PubMed
    Score: 0.062
  39. Elmarakby AA, Imig JD. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci (Lond). 2010 Feb; 118(4):291-301.
    View in: PubMed
    Score: 0.062
  40. Cert?kov? Ch?bov? V, Kramer HJ, Vaneckov? I, Thumov? M, Skaroupkov? P, Tesar V, Falck JR, Imig JD, Cervenka L. The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res. 2007; 30(5):335-46.
    View in: PubMed
    Score: 0.052
  41. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005 Oct; 46(4):975-81.
    View in: PubMed
    Score: 0.046
  42. Zhao X, Cook AK, Field M, Edwards B, Zhang S, Zhang Z, Pollock JS, Imig JD, Inscho EW. Impaired Ca2+ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension. Hypertension. 2005 Sep; 46(3):562-8.
    View in: PubMed
    Score: 0.046
  43. Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond). 2004 Dec; 107(6):561-70.
    View in: PubMed
    Score: 0.043
  44. Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2005 Jan; 288(1):R188-96.
    View in: PubMed
    Score: 0.043
  45. Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes Res. 2004 Aug; 12(8):1278-89.
    View in: PubMed
    Score: 0.042
  46. Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. J Clin Invest. 2003 Dec; 112(12):1895-905.
    View in: PubMed
    Score: 0.040
  47. Yiu SS, Zhao X, Inscho EW, Imig JD. 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. J Lipid Res. 2003 Dec; 44(12):2391-9.
    View in: PubMed
    Score: 0.040
  48. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension. 2003 Oct; 42(4):594-9.
    View in: PubMed
    Score: 0.040
  49. Harrison-Bernard LM, Imig JD, Carmines PK. Renal AT1 receptor protein expression during the early stage of diabetes mellitus. Int J Exp Diabetes Res. 2002 Apr-Jun; 3(2):97-108.
    View in: PubMed
    Score: 0.036
  50. Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG. Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Hypertension. 2002 Jan; 39(1):116-21.
    View in: PubMed
    Score: 0.035
  51. Chiang KC, Imig JD, Kalantar-Zadeh K, Gupta A. Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Curr Opin Nephrol Hypertens. 2022 01 01; 31(1):36-46.
    View in: PubMed
    Score: 0.035
  52. Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, Imig JD, Villalba JM, Zeldin DC, Hammock BD, Haj FG. Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochim Biophys Acta Gen Subj. 2017 Nov; 1861(11 Pt A):2758-2765.
    View in: PubMed
    Score: 0.026
  53. J?chov? ?, Kopkan L, Huskov? Z, Dole?elov? ?, Neck?r J, Kujal P, Vernerov? Z, Kramer HJ, Sadowski J, Kompanowska-Jezierska E, Reddy RN, Falck JR, Imig JD, Cervenka L. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2016 10; 34(10):2008-25.
    View in: PubMed
    Score: 0.025
  54. Sporkov? A, Reddy RN, Falck JR, Imig JD, Kopkan L, Sadowski J, Cervenka L. Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. Am J Med Sci. 2016 05; 351(5):513-9.
    View in: PubMed
    Score: 0.024
  55. Al?nov? P, Huskov? Z, Kopkan L, Sporkov? A, J?chov? ?, Neck?r J, Imig JD, Klevstig M, Kol?r F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovsk? V, Cervenkov? L, Kujal P, Vernerov? Z, Cervenka L. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascul Pharmacol. 2015 Oct; 73:45-56.
    View in: PubMed
    Score: 0.023
  56. Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.
    View in: PubMed
    Score: 0.022
  57. Kim J, Imig JD, Yang J, Hammock BD, Padanilam BJ. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. Am J Physiol Renal Physiol. 2014 Oct 15; 307(8):F971-80.
    View in: PubMed
    Score: 0.021
  58. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013 Sep; 62(3):285-97.
    View in: PubMed
    Score: 0.020
  59. Honetschl?gerov? Z, Sporkov? A, Kopkan L, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Ch?bov? VC, Tesar V, Cervenka L. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2011 Aug; 29(8):1590-601.
    View in: PubMed
    Score: 0.017
  60. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2008 Jan; 294(1):R76-83.
    View in: PubMed
    Score: 0.013
  61. Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, Pollock DM, Ergul A. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol. 2006 Feb; 290(2):R435-41.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.